Tumour-infiltrating lymphocyte therapy landscape: prospects and challenges
Tumour-infiltrating lymphocyte (TIL) therapy has emerged as a promising adoptive cell transfer strategy for solid tumours. The recent accelerated approval of lifileucel by the Food and Drug Administration marks a significant milestone in the clinical application of TIL therapy. This review comprehen...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-08-01
|
| Series: | BMJ Oncology |
| Online Access: | https://bmjoncology.bmj.com/content/4/1/e000566.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849398241898004480 |
|---|---|
| author | Arkadiusz Z Dudek Jeffrey Johnson Ruqin Chen Ali Rezazadeh |
| author_facet | Arkadiusz Z Dudek Jeffrey Johnson Ruqin Chen Ali Rezazadeh |
| author_sort | Arkadiusz Z Dudek |
| collection | DOAJ |
| description | Tumour-infiltrating lymphocyte (TIL) therapy has emerged as a promising adoptive cell transfer strategy for solid tumours. The recent accelerated approval of lifileucel by the Food and Drug Administration marks a significant milestone in the clinical application of TIL therapy. This review comprehensively examines the historical development, biology, clinical efficacy, safety and limitations of TIL therapy. We explore advancements in TIL manufacturing, including novel culture techniques, genetic modifications and automation, to enhance scalability and effectiveness. Despite promising results, TIL therapy faces challenges such as high-dose interleukin-2 toxicity, complex manufacturing processes and immune evasion mechanisms. Emerging strategies, including checkpoint inhibitor combinations, engineered TIL constructs and metabolic reprogramming, aim to improve TIL therapeutic efficacy. This review provides insights into the evolving landscape of TIL therapy and its potential to enhance current cancer immunotherapy. |
| format | Article |
| id | doaj-art-f4e5b595332c47b79cff288b2eeddeea |
| institution | Kabale University |
| issn | 2752-7948 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Oncology |
| spelling | doaj-art-f4e5b595332c47b79cff288b2eeddeea2025-08-20T03:38:39ZengBMJ Publishing GroupBMJ Oncology2752-79482025-08-014110.1136/bmjonc-2024-000566Tumour-infiltrating lymphocyte therapy landscape: prospects and challengesArkadiusz Z Dudek0Jeffrey Johnson1Ruqin Chen2Ali Rezazadeh3Aff2 grid.185648.60000000121750319University of Illinois Cancer Center Chicago IL USA1School of Pharmacy, University of Wisconsin, Madison, WI, USADepartment of Medicine, Mayo Clinic, Jacksonville, Florida, USAMedical Oncology, Mayo Clinic, Rochester, Minnesota, USATumour-infiltrating lymphocyte (TIL) therapy has emerged as a promising adoptive cell transfer strategy for solid tumours. The recent accelerated approval of lifileucel by the Food and Drug Administration marks a significant milestone in the clinical application of TIL therapy. This review comprehensively examines the historical development, biology, clinical efficacy, safety and limitations of TIL therapy. We explore advancements in TIL manufacturing, including novel culture techniques, genetic modifications and automation, to enhance scalability and effectiveness. Despite promising results, TIL therapy faces challenges such as high-dose interleukin-2 toxicity, complex manufacturing processes and immune evasion mechanisms. Emerging strategies, including checkpoint inhibitor combinations, engineered TIL constructs and metabolic reprogramming, aim to improve TIL therapeutic efficacy. This review provides insights into the evolving landscape of TIL therapy and its potential to enhance current cancer immunotherapy.https://bmjoncology.bmj.com/content/4/1/e000566.full |
| spellingShingle | Arkadiusz Z Dudek Jeffrey Johnson Ruqin Chen Ali Rezazadeh Tumour-infiltrating lymphocyte therapy landscape: prospects and challenges BMJ Oncology |
| title | Tumour-infiltrating lymphocyte therapy landscape: prospects and challenges |
| title_full | Tumour-infiltrating lymphocyte therapy landscape: prospects and challenges |
| title_fullStr | Tumour-infiltrating lymphocyte therapy landscape: prospects and challenges |
| title_full_unstemmed | Tumour-infiltrating lymphocyte therapy landscape: prospects and challenges |
| title_short | Tumour-infiltrating lymphocyte therapy landscape: prospects and challenges |
| title_sort | tumour infiltrating lymphocyte therapy landscape prospects and challenges |
| url | https://bmjoncology.bmj.com/content/4/1/e000566.full |
| work_keys_str_mv | AT arkadiuszzdudek tumourinfiltratinglymphocytetherapylandscapeprospectsandchallenges AT jeffreyjohnson tumourinfiltratinglymphocytetherapylandscapeprospectsandchallenges AT ruqinchen tumourinfiltratinglymphocytetherapylandscapeprospectsandchallenges AT alirezazadeh tumourinfiltratinglymphocytetherapylandscapeprospectsandchallenges |